A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Lymphoma, B-CellLymphoma, T-Cell
Interventions
DRUG

STP938

Small molecule

Trial Locations (15)

10065

RECRUITING

Memorial Sloan Kettering, New York

34232

RECRUITING

Florida Cancer Specialists, Sarasota

75610

RECRUITING

Hôpital Saint-Louis, Paris

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

Unknown

RECRUITING

The Centre Léon Bérard, Lyon

RECRUITING

Institut Paoli Calmettes, Marseille

RECRUITING

CHU de Nantes, Nantes

RECRUITING

Institut Gustave Roussy, Villejuif

RECRUITING

University Hospitals of Leicester NHS Trust, Leicester

RECRUITING

Imperial College / Clinical Trials Unit, Hammersmith Hospital, London

RECRUITING

The Christie, Manchester

RECRUITING

Nottingham City Hospital, Nottingham

RECRUITING

Churchill Hospital, Oxford

RECRUITING

Derriford Hospital, Plymouth

RECRUITING

The Royal Marsden, Sutton

All Listed Sponsors
lead

Step Pharma, SAS

INDUSTRY